@article{087d49adf138412c8b8de51c3c5992a8,
title = "Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine",
abstract = "Background & AIMS: Antiviral treatment criteria are based on disease progression risk, and hepatocellular carcinoma (HCC) surveillance recommendations for patients with chronic hepatitis B (CHB) without cirrhosis is based on an annual incidence threshold of 0.2%. However, accurate and precise disease progression estimate data are limited. Thus, we aimed to determine rates of cirrhosis and HCC development stratified by age, sex, treatment status, and disease activity based on the 2018 American Association for the Study of Liver Diseases and 2017 European Association for the Study of the Liver guidelines. Methods: We analyzed 18,338 patients (8914 treated, 9424 untreated) from 6 centers from the United States and 27 centers from Asia-Pacific countries. The Kaplan-Meier method was used to estimate annual progression rates to cirrhosis or HCC in person-years. Results: The cohort was 63% male, with a mean age of 46.19 years, with baseline cirrhosis of 14.3% and median follow up of 9.60 years. By American Association for the Study of Liver Diseases criteria, depending on age, sex, and disease activity, annual incidence rates ranged from 0.07% to 3.94% for cirrhosis, from 0.04% to 2.19% for HCC in patients without cirrhosis, and from 0.40% to 8.83% for HCC in patients with cirrhosis. Several subgroups of patients without cirrhosis including males younger than 40 years of age and females younger than 50 years of age had annual HCC risk near or exceeding 0.2%. Similar results were found using European Association for the Study of the Liver criteria. Conclusion: There is great variability in CHB disease progression rates even among “lower-risk” populations. Future CHB modeling studies, public health planning, and HCC surveillance recommendation should be based on more precise disease progression rates based on sex, age, and disease activity, plus treatment status.",
author = "Jiyoon Park and Le, {An K.} and Tseng, {Tai Chung} and Yeh, {Ming Lun} and Jun, {Dae Won} and Huy Trinh and Wong, {Grace L.H.} and Chen, {Chien Hung} and Peng, {Cheng Yuan} and Kim, {Sung Eun} and Hyunwoo Oh and Kwak, {Min Sun} and Cheung, {Ka Shing} and Hidenori Toyoda and Hsu, {Yao Chun} and Jeong, {Jae Yoon} and Yoon, {Eileen L.} and Teerapat Ungtrakul and Jian Zhang and Qing Xie and Ahn, {Sang Bong} and Masaru Enomoto and Shim, {Jae Jun} and Chris Cunningham and Jeong, {Soung Won} and Cho, {Yong Kyun} and Eiichi Ogawa and Rui Huang and Lee, {Dong Hyun} and Hirokazu Takahashi and Tsai, {Pei Chien} and Huang, {Chung Feng} and Dai, {Chia Yen} and Tseng, {Cheng Hao} and Satoshi Yasuda and Ritsuzo Kozuka and Jiayi Li and Christopher Wong and Wong, {Clifford C.} and Changqing Zhao and Joseph Hoang and Yuichiro Eguchi and Chao Wu and Yasuhito Tanaka and Ed Gane and Tawesak Tanwandee and Ramsey Cheung and Yuen, {Man Fung} and Lee, {Hyo Suk} and Yu, {Ming Lung} and Kao, {Jia Horng} and Yang, {Hwai I.} and Nguyen, {Mindie H.}",
note = "Funding Information: Funding This study was supported partially by Kaohsiung Medical University (KMU) Research Center Grants (KMU investigators): Center for Liquid Biopsy ( KMU TC108B06 ), Cohort Research Center ( KMU-TC108B07 and KMU-DK109002 ), and Center for Liquid Biopsy and Cohort Research ( KMU-TC109B05 ). Funding Information: Conflicts of interest These authors disclose the following: Hwai-I Yang has received research funding from Gilead Sciences, Inc. Ming-Lung Yu has received research support from Abbott, BMS, Gilead, and Merck; served as a consultant or on the advisory board for AbbVie, Abbott, Ascletis, BMS, Gilead, and Merck; and served as a speaker for AbbVie, Abbott, BMS, Gilead, Merck, and IPSEN. Hideonori Toyoda has served as a speaker for AbbVie and Gilead. Dong-Hyun Lee has received research funding from Gilead Sciences and Korea Pharma. Sung-Eun Kim has received research funding from Daewoong, served as consultant for Chonggwendang, and served as a speaker for Daewoong. Huy Trinh has received research funding from, served as a consultant and speaker for, and owns stock in Gilead. Cheng-Yuan Peng has served as a consultant or the advisory board for AbbVie, Bristol-Myers Squibb, Gilead, Merck Sharp & Dohme, and Roche. Tai-Chung Tseng has served on speaker{\textquoteright}s bureau for AbbVie, Bristol-Myers Squibb, and Gilead Sciences; and received research funding from and served as a consulant for Gilead Sciences. Ramsey Cheung has received a research grant from Gilead. Mindie H. Nguyen has received research support from Gilead, Pfizer, Enanta, B.K. Kee Foundation, National Cancer Institute, Glycotest, and Vir; and served as a consultant or on the advisory board for Novartis, Bayer, Eisai, Gilead, Janssen, Laboratory of Advanced Medicine, Spring Bank, Exact Sciences, Helio, and Intercept. Teerapat Ungtrakul has received research funding from AstraZeneca and Roche. Tawesak Tanwandee has received Research grants from Roche, Janssen, and Merck. Chia-Yen Dai has served as a consultant for AbbVie and as a speaker for AbbVie, Merck, BMS, and Gilead. Man-Fung Yuen has served as a consultant for AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myers Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen Pharmaceutical, Merck Sharp and Dohme, Clear B Therapeutics, and Springbank Pharmaceutical. Chao Wu has received research funding from Gilead Sciences. Jia-Horng Kao has received research funding from Gilead Sciences and BMS; served as a consultant for Gilead Sciences, Roche, AbbVie, and Arbutus; and served as a speaker for BMS, Gilead Sciences, MSD, AbbVie, and Fujirebio. Yasuhito Tanaka has received research funding from Janssen Pharmaceutical KK, Gilead Sciences, and GlaxoSmithKline PLC; and served as a speaker for Gilead Sciences and FUJIREBIO Inc. Grace Wong has received research funding from and served as a consultant for Gilead Sciences; and served as a speaker for Abbott, AbbVie, Bristol-Myers Squibb, Echosense, Furui, Gilead Sciences, Janssen Pharmaceutical, and Roche. Yao-Chun Hsu has received research funding from and served as a consultant for Gilead Sciences; and served as a speaker for AbbVie, Bristol-Myers Squibb, and Gilead Sciences. Eiichi Ogawa has served as a speaker for Gilead Sciences. The remaining authors disclose no conflicts. Funding Information: Funding This study was supported partially by Kaohsiung Medical University (KMU) Research Center Grants (KMU investigators): Center for Liquid Biopsy (KMU TC108B06), Cohort Research Center (KMU-TC108B07 and KMU-DK109002), and Center for Liquid Biopsy and Cohort Research (KMU-TC109B05). Conflicts of interest These authors disclose the following: Hwai-I Yang has received research funding from Gilead Sciences, Inc. Ming-Lung Yu has received research support from Abbott, BMS, Gilead, and Merck; served as a consultant or on the advisory board for AbbVie, Abbott, Ascletis, BMS, Gilead, and Merck; and served as a speaker for AbbVie, Abbott, BMS, Gilead, Merck, and IPSEN. Hideonori Toyoda has served as a speaker for AbbVie and Gilead. Dong-Hyun Lee has received research funding from Gilead Sciences and Korea Pharma. Sung-Eun Kim has received research funding from Daewoong, served as consultant for Chonggwendang, and served as a speaker for Daewoong. Huy Trinh has received research funding from, served as a consultant and speaker for, and owns stock in Gilead. Cheng-Yuan Peng has served as a consultant or the advisory board for AbbVie, Bristol-Myers Squibb, Gilead, Merck Sharp & Dohme, and Roche. Tai-Chung Tseng has served on speaker's bureau for AbbVie, Bristol-Myers Squibb, and Gilead Sciences; and received research funding from and served as a consulant for Gilead Sciences. Ramsey Cheung has received a research grant from Gilead. Mindie H. Nguyen has received research support from Gilead, Pfizer, Enanta, B.K. Kee Foundation, National Cancer Institute, Glycotest, and Vir; and served as a consultant or on the advisory board for Novartis, Bayer, Eisai, Gilead, Janssen, Laboratory of Advanced Medicine, Spring Bank, Exact Sciences, Helio, and Intercept. Teerapat Ungtrakul has received research funding from AstraZeneca and Roche. Tawesak Tanwandee has received Research grants from Roche, Janssen, and Merck. Chia-Yen Dai has served as a consultant for AbbVie and as a speaker for AbbVie, Merck, BMS, and Gilead. Man-Fung Yuen has served as a consultant for AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myers Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen Pharmaceutical, Merck Sharp and Dohme, Clear B Therapeutics, and Springbank Pharmaceutical. Chao Wu has received research funding from Gilead Sciences. Jia-Horng Kao has received research funding from Gilead Sciences and BMS; served as a consultant for Gilead Sciences, Roche, AbbVie, and Arbutus; and served as a speaker for BMS, Gilead Sciences, MSD, AbbVie, and Fujirebio. Yasuhito Tanaka has received research funding from Janssen Pharmaceutical KK, Gilead Sciences, and GlaxoSmithKline PLC; and served as a speaker for Gilead Sciences and FUJIREBIO Inc. Grace Wong has received research funding from and served as a consultant for Gilead Sciences; and served as a speaker for Abbott, AbbVie, Bristol-Myers Squibb, Echosense, Furui, Gilead Sciences, Janssen Pharmaceutical, and Roche. Yao-Chun Hsu has received research funding from and served as a consultant for Gilead Sciences; and served as a speaker for AbbVie, Bristol-Myers Squibb, and Gilead Sciences. Eiichi Ogawa has served as a speaker for Gilead Sciences. The remaining authors disclose no conflicts. Publisher Copyright: {\textcopyright} 2022 AGA Institute",
year = "2022",
month = apr,
doi = "10.1016/j.cgh.2021.05.062",
language = "English",
volume = "20",
pages = "874--885.e4",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "4",
}
